Efficacy Evaluation Of Neoadjuvant Chemotherapy For Gastric Cancer

Objective:To investigate the efficacy and short-term prognosis of two regimens?oxaliplatin combined with tigiao?and three regimens?paclitaxel combined with oxaliplatin and tigio?in the treatment of advanced gastric cancer.Methods:the medical records of 53 patients with advanced gastric cancer treated in the Cancer Hospital affiliated to Xinjiang Medical University from January 2015 to January 2018 were analyzed retrospectively.according to the neoadjuvant chemotherapy regimen,they were divided into control group and observation group.A total of 23 patients in the control group were treated with three-drug chemotherapy regimen,and 30 patients in the observation group were treated with two-drug chemotherapy regimen.The short-term efficacy was compared by comparing R₀ resection rate,1-year survival rate?OS?and?DFS?.Results:there was no significant difference between the two groups in 14 cases of radical resection and 20 cases of radical resection in the observation group?P>0.05?.Results:there was no significant difference between the two groups?P>0.05?.Results:there was no significant difference in the resection rate between the two groups?P>0.05?.Short-term prognosis:25 cases survived one year with one year survival rate,and 19 cases survived one year after neoadjuvant chemotherapy?paclitaxel combined with oxaliplatin and tigiao?.There was no significant difference in one year survival rate??OS?82.61%?between the two regimens and neoadjuvant chemotherapy?paclitaxel combined with oxaliplatin and tigiao?.There was no significant difference in the one-year survival rate between the two regimens?paclitaxel combined with oxaliplatin and tigiao?.The one-year progression-free survival rate of?DFS?:was 56.67%in?DFS?and 56.52%in paclitaxel combined with oxaliposide combined with tigio.There was no significant difference between the two regimens?paclitaxel combined with oxaliplatin combined with tigio?in the one-year progression-free survival rate?P>0.05?,and there was no significant difference in the one-year progression-free survival rate between the two regimens?paclitaxel combined with oxaliplatin combined with tigio?.Conclusion:there is no significant difference in the curative effect and short-term prognosis between the two regimens and the three regimens in the treatment of advanced gastric cancer.